FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304080602> ?p ?o ?g. }

• W4304080602 endingPage "e002639" @default.
• W4304080602 startingPage "e002639" @default.
• W4304080602 abstract "Objective The level of neutralising capacity against Omicron BA.1 and BA.2 after third COVID-19 vaccination in patients on paused or continuous methotrexate (MTX) therapy is unclear. Methods In this observational cohort study, neutralising serum activity against SARS-CoV-2 wild-type (Wu01) and variant of concern Omicron BA.1 and BA.2 were assessed by pseudovirus neutralisation assay before, 4 and 12 weeks after mRNA booster immunisation in 50 rheumatic patients on MTX, 26 of whom paused the medication. 44 non-immunosuppressed persons (NIP) served as control group. Results While the neutralising serum activity against SARS-CoV-2 Wu01 and Omicron variants increased 67–73 fold in the NIP after booster vaccination, the serum activity in patients receiving MTX increased only 20–23 fold. Patients who continued MTX treatment during vaccination had significantly lower neutralisation against all variants at weeks 4 and 12 compared with patients who paused MTX and the control group, except for BA.2 at week 12. Patients who paused MTX reached comparably high neutralising capacities as NIP, except for Wu01 at week 12. The duration of the MTX pause after—not before—was associated with a significantly higher neutralisation capacity against all three variants, with an optimal duration at 10 days after vaccination. Conclusion Patients pausing MTX after COVID-19 booster showed a similar vaccine response to NIP. Patients who continued MTX demonstrated an impaired response indicating a potentially beneficial second booster vaccination. Our data also suggest that a 1 week MTX break is sufficient if the last administration of MTX occurs 1–3 days before vaccination." @default.
• W4304080602 created "2022-10-10" @default.
• W4304080602 creator A5002583726 @default.
• W4304080602 creator A5005043574 @default.
• W4304080602 creator A5022459181 @default.
• W4304080602 creator A5023217663 @default.
• W4304080602 creator A5025690932 @default.
• W4304080602 creator A5027462991 @default.
• W4304080602 creator A5033077051 @default.
• W4304080602 creator A5038457817 @default.
• W4304080602 creator A5067716705 @default.
• W4304080602 creator A5072489793 @default.
• W4304080602 creator A5073594523 @default.
• W4304080602 creator A5074607200 @default.
• W4304080602 creator A5077100105 @default.
• W4304080602 creator A5078399821 @default.
• W4304080602 creator A5086835391 @default.
• W4304080602 date "2022-10-01" @default.
• W4304080602 modified "2023-10-14" @default.
• W4304080602 title "Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination" @default.
• W4304080602 cites W2610310220 @default.
• W4304080602 cites W2792992921 @default.
• W4304080602 cites W3020828664 @default.
• W4304080602 cites W3163971529 @default.
• W4304080602 cites W3164342759 @default.
• W4304080602 cites W3164513520 @default.
• W4304080602 cites W3165645649 @default.
• W4304080602 cites W3174430269 @default.
• W4304080602 cites W3196356596 @default.
• W4304080602 cites W4200247405 @default.
• W4304080602 cites W4200262223 @default.
• W4304080602 cites W4205283268 @default.
• W4304080602 cites W4207048578 @default.
• W4304080602 cites W4210832067 @default.
• W4304080602 cites W4213455529 @default.
• W4304080602 cites W4220689791 @default.
• W4304080602 cites W4220811758 @default.
• W4304080602 cites W4220832922 @default.
• W4304080602 cites W4225386205 @default.
• W4304080602 cites W4225413377 @default.
• W4304080602 cites W4225729728 @default.
• W4304080602 cites W4226229183 @default.
• W4304080602 cites W4283783451 @default.
• W4304080602 doi "https://doi.org/10.1136/rmdopen-2022-002639" @default.
• W4304080602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36216410" @default.
• W4304080602 hasPublicationYear "2022" @default.
• W4304080602 type Work @default.
• W4304080602 citedByCount "9" @default.
• W4304080602 countsByYear W43040806022022 @default.
• W4304080602 countsByYear W43040806022023 @default.
• W4304080602 crossrefType "journal-article" @default.
• W4304080602 hasAuthorship W4304080602A5002583726 @default.
• W4304080602 hasAuthorship W4304080602A5005043574 @default.
• W4304080602 hasAuthorship W4304080602A5022459181 @default.
• W4304080602 hasAuthorship W4304080602A5023217663 @default.
• W4304080602 hasAuthorship W4304080602A5025690932 @default.
• W4304080602 hasAuthorship W4304080602A5027462991 @default.
• W4304080602 hasAuthorship W4304080602A5033077051 @default.
• W4304080602 hasAuthorship W4304080602A5038457817 @default.
• W4304080602 hasAuthorship W4304080602A5067716705 @default.
• W4304080602 hasAuthorship W4304080602A5072489793 @default.
• W4304080602 hasAuthorship W4304080602A5073594523 @default.
• W4304080602 hasAuthorship W4304080602A5074607200 @default.
• W4304080602 hasAuthorship W4304080602A5077100105 @default.
• W4304080602 hasAuthorship W4304080602A5078399821 @default.
• W4304080602 hasAuthorship W4304080602A5086835391 @default.
• W4304080602 hasBestOaLocation W43040806021 @default.
• W4304080602 hasConcept C121332964 @default.
• W4304080602 hasConcept C12590561 @default.
• W4304080602 hasConcept C126322002 @default.
• W4304080602 hasConcept C1276947 @default.
• W4304080602 hasConcept C14086860 @default.
• W4304080602 hasConcept C203014093 @default.
• W4304080602 hasConcept C203165030 @default.
• W4304080602 hasConcept C22070199 @default.
• W4304080602 hasConcept C2522874641 @default.
• W4304080602 hasConcept C2779134260 @default.
• W4304080602 hasConcept C2781059491 @default.
• W4304080602 hasConcept C3008058167 @default.
• W4304080602 hasConcept C32611913 @default.
• W4304080602 hasConcept C524204448 @default.
• W4304080602 hasConcept C71924100 @default.
• W4304080602 hasConcept C72563966 @default.
• W4304080602 hasConceptScore W4304080602C121332964 @default.
• W4304080602 hasConceptScore W4304080602C12590561 @default.
• W4304080602 hasConceptScore W4304080602C126322002 @default.
• W4304080602 hasConceptScore W4304080602C1276947 @default.
• W4304080602 hasConceptScore W4304080602C14086860 @default.
• W4304080602 hasConceptScore W4304080602C203014093 @default.
• W4304080602 hasConceptScore W4304080602C203165030 @default.
• W4304080602 hasConceptScore W4304080602C22070199 @default.
• W4304080602 hasConceptScore W4304080602C2522874641 @default.
• W4304080602 hasConceptScore W4304080602C2779134260 @default.
• W4304080602 hasConceptScore W4304080602C2781059491 @default.
• W4304080602 hasConceptScore W4304080602C3008058167 @default.
• W4304080602 hasConceptScore W4304080602C32611913 @default.
• W4304080602 hasConceptScore W4304080602C524204448 @default.
• W4304080602 hasConceptScore W4304080602C71924100 @default.

• next